Skip Navigation

Neuro-Oncology 1999 1(1):69-80; doi:10.1093/neuonc/1.1.69
© 1999 by Society
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Levin, V. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Levin, V. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1999 by the Society forNeuro-Oncology

Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage:The past decade and where we are heading

Victor A. Levin2

Department of Neuro-Oncology and the Brain Tumor Center, M.D.Anderson Cancer Center, University of Texas, Houston, TX 77030

2 Address correspondence and reprint requests to Victor A. Levin, MD, Departmentof Neuro-Oncology-100, M.D. Anderson Cancer Center, University of Texas, 1515Holcombe Boulevard, Houston, TX 77030.


  Abstract

Over the past three decades, we have made great strides in the treatment ofmost, but not all, brain tumors. Dramatic advances have occurred in diagnosticimaging, neurosurgery, neuroanesthesia, radiotherapy, and chemotherapy for CNStumors. Unfortunately, our progress has not yet met our expectations. Becauseof the infiltrative nature of most primary brain tumors, neurosurgery cannever be expected to be curative for the majority of gliomas. Becauseinfiltrative tumors interdigitate with normal brain cells and are not highlysensitive to irradiation, one cannot expect radiotherapy to be curativewithout serious damage to normal brain cells. The hope for a cure, then, restswith chemotherapy. Those who administer chemotherapy to patients with CNStumors fully expect that, in time, long-term survival and, ultimately, thecure will become an everyday reality. To achieve that reality, however, newtreatment concepts and drugs are needed.

Received July 14, 1998; Accepted September 24, 1998


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
A. A. Brandes, E. Franceschi, A. Tosoni, M. E. Hegi, and R. Stupp
Epidermal Growth Factor Receptor Inhibitors in Neuro-oncology: Hopes and Disappointments
Clin. Cancer Res., February 15, 2008; 14(4): 957 - 960.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncologyHome page
S. L. Chua, M. A. Rosenthal, S. S. Wong, D. M. Ashley, A.-m. Woods, A. Dowling, and L. M. Cher
Phase 2 study of temozolomide and Caelyx in patients with recurrentglioblastoma multiforme
Neuro Oncology, January 1, 2004; 6(1): 38 - 43.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Bello, C. Giussani, G. Carrabba, M. Pluderi, V. Lucini, M. Pannacci, D. Caronzolo, G. Tomei, R. Villani, F. Scaglione, et al.
Suppression of Malignant Glioma Recurrence in a Newly Developed Animal Model by Endogenous Inhibitors
Clin. Cancer Res., November 1, 2002; 8(11): 3539 - 3548.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.